digiDEM Bavaria Statement on Lecanemab
The decision by the Joint Federal Committee (G-BA) of February 19, 2026, to classify the additional benefit of Lecanemab as ‚not proven‘ confirms the skepticism of the digiDEM project management regarding the clinical relevance of this therapy. While the only study available so far on Lecanemab shows a statistically significant difference between the drug and a placebo at the end of the study...
